skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits

Original Research

(1666) Views  (339) Full article downloads

Authors: Abayomi B Ogundele, Mark C Jasek

Published Date December 2010 Volume 2010:4 Pages 1447 - 1450
DOI: http://dx.doi.org/10.2147/OPTH.S15521

Abayomi B Ogundele, Mark C Jasek
Alcon Research Ltd, Fort Worth, TX, USA

Purpose: The purpose of this study was to compare the aqueous humor concentrations of bimatoprost acid after topical instillation in rabbits of bimatoprost ophthalmic solution 0.01% and bimatoprost ophthalmic solution 0.03%, two commercially available intraocular pressure-lowering medications.
Methods: Male Dutch Belted rabbits were divided into two treatment groups (four rabbits/eight eyes per group): bimatoprost 0.01% and bimatoprost 0.03%. Thirty microliters (µL) of study medication was to pically instilled into both eyes of each animal. Thirty minutes and 90 minutes after instillation, aqueous humor samples were collected. These samples were analyzed by reverse-phase high-performance liquid chromatography for bimatoprost acid concentration.
Results: Following a single topical ocular instillation, the bimatoprost 0.01% formulation had a lower mean aqueous humor concentration of bimatoprost acid than the bimatoprost 0.03% formulation at both 30 minutes (11.5 ± 2.1 ng/mL versus 37.8 ± 28.8 ng/mL; P = 0.17) and 90 minutes (20.8 ± 5.7 ng/mL versus 45.8 ± 14.3 ng/mL; P = 0.03) after topical instillation.
Conclusions: Topical ocular instillation of bimatoprost 0.01% produced significantly lower bimatoprost acid concentration in the aqueous humor of rabbits than bimatoprost 0.03%, despite the 4-fold increase of benzalkonium chloride contained in bimatoprost 0.01%.

Keywords: aqueous humor, benzalkonium chloride, bimatoprost, pharmacokinetics, preclinical, prostaglandin analog




 

Other articles by Dr Abayomi Ogundele



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Bacterial conjunctivitis
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension